Skip to main content

Sponsored by Lilly

Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer: 6-Part Podcast Series

Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer

We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer.

All Episodes

Neil M. Iyengar, MD

Neil M. Iyengar, MD

Director, Survivorship Services, Winship Cancer Institute of Emory University
Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, GA
Seth Wander, MD, PhD

Seth Wander, MD, PhD

Director, Precision Medicine, Termeer Center for Targeted Therapies
Director, Translational Research, Breast Oncology Program
Assistant Professor of Medicine, Harvard Medical School
Massachusetts General Hospital
Boston, MA